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Antitumor alkylphospholipid analogs (APLs), also known collectively as antitumor lipids (ATLs), 
were originally synthesized as synthetic ether-linked metabolically stable analogs of 
lysophospholipids in the late 1960’s as immune modulators, but later on they were shown to 
destroy tumor cells in the late 1970’s. The mechanisms underlying the antitumor activity of 
APLs remained an enigma until the 1990’s, when it was found that the APL edelfosine was a 
potent inducer of apoptosis in tumor cells, whereas normal cells were not affected. This 
selectivity was mainly due to a preferential uptake of the ether lipid edelfosine by cancer cells, 
by mechanisms that remain to be fully elucidated. In contrast to most of the antitumor drugs of 
the time, it was found that APLs did not target DNA, but acted at the cell membrane. These 
findings made this ether lipid unique compared to the other anticancer drugs of the time, and 
rekindled a great interest in these APLs as promising and selective antitumor drugs. At the 
beginning of the synthesis of APLs, the ester linkages at C1 and C2 of the glycerol backbone of 
lysophosphatidylcholine (1-acyl-sn-glycero-3-phosphocholine) were replaced for ether bonds to 
yield analogs resistant to the action of acyltransferases or lysophospholipases. Among these 
synthesized ether lipid analogs of lysophosphatidylcholine, edelfosine (1-O-octadecyl-2-O-
methylrac-glycero-3-phosphocholine, initially known as ET-18-OCH3) resulted the most 
effective antitumor drug, which became, and still is, the gold standard for assessing the 
antitumor activities of new APLs in in vitro and in vivo trials. The first synthesis of edelfosine was 
reported in 1969, and it is interesting to mention that the chemical structure of this synthetic 
compound surprisingly turned out to be very close to that of the physiological molecule known 
as platelet-activating factor (PAF), a major biologically active phospholipid inflammatory 
mediator whose structure was identified in 1979, that is a decade after the synthesis of 
edelfosine. The only difference between PAF and edelfosine lies at C2, namely an acetoxy 
group bound through an ester bond to the glycerol backbone in PAF, whereas edelfosine 
contains a methoxy group bound through an ether linkage to C2. From the chemical point of 
view, APLs were primarily distributed into two main classes: a) the alkyl ether phospholipids 
(AEPs), also named as antitumor ether lipids (AELs) or alkyl-lysophospholipid analogs (ALPs), 
which contained ether bonds in the phospholipid glycerol backbone, as exemplified by 
edelfosine ; b) the alkylphosphocholines (APCs), which lacked the glycerol backbone and were 
formed by a simple long-chain alcohol esterified to a phosphobase, as exemplified by 
hexadecylphosphocholine (HPC; miltefosine) that resulted to be the minimal structural 
requirement of APLs to exert antitumor activity. So far, miltefosine, under the trademark name of 
Miltex®, is the only APL that has been approved to enter the clinic as antitumor drug, being 
used for the topical treatment of metastatic skin lesions in breast cancer. Thus, a major 
difference between the above two classes of APLs lies in the lack of a glycerol 
backbone in APCs. The above two major APL categories are considered as the first 
and second generation of APLs, respectively. Three new drugs have been synthesized 
as variants of miltefosine, considered as the third-generation APLs, and have been 
named as: perifosine (octadecyl-(1,1-dimethylpiperidino-4-yl)-phosphate, D-21266), 
where the choline moiety of miltefosine is replaced by a heterocyclic piperidine group; 
erucylphosphocholine, that contains a longer hydrocarbon chain than miltefosine with a 
cis double bond; and its closely related congener erufosine 
(erucylphosphohomocholine, erucylphospho-N,N,N-trimethylpropylammonium, ErPC3) 
(Veenman et al., this issue). These third-generation APLs, especially perifosine, show 
promise as putative anticancer drugs, and are currently in preclinical and clinical trials 
(Fensterle et al., this issue).  
 
 
 
 
 
 
 
More recently, a novel group of APLs has been synthesized that contain a sugar 
moiety, known as glycosylated antitumor ether lipids (GAELs) and considered as 
fourth-generation APLs, that display significant antitumor activities in the concentration 
range of the gold standard edelfosine. Two major classes of GAELs can be 
distinguished: a) glycosydated phospholipids (Semini et al., this issue), that contain 
carbohydrates or carbohydrate-related molecules at the sn-2 position of the glycerol 
backbone, inositol-C2-plateletactivating factor (Ino-C2-PAF) (1-O-octadecyl-2-O-(2-
(myo-inositolylethyl)-sn-glycero-3-(R/S)-phosphatidylcholine) exhibiting the highest 
antitumor efficacy; b) non-phosphorous GAELs (Arthur and Bittman, this issue), that 
have a sugar moiety in place of the phosphobase present in ALPs, 1-O-hexadecyl-2-O-
methyl-3-O-(2’- amino-2’-deoxy-β-D-glucopyranosyl)-sn-glycerol (ET-16-OCH3-Gln) 
being the most active compound of this new family to date. ALPs and APCs kill cancer 
cells by inducing apoptosis, whereas GAELs appear to kill cells through apoptosis-
independent mechanisms. All of these molecules, which are distinguished by their low 
rates of metabolism in vitro and in vivo, are dealt with in the present thematic issue in 
order to provide a comprehensive overview of the state of the art on this promising 
family of compounds. The eleven articles included in this thematic issue provide up-to-
date research on the field of APLs, involving basic, translational and clinical work. The 
distinct original and review articles, comprised in this thematic issue, address 
numerous conceptual and experimental considerations on how these molecules target 
and affect membrane-related events that eventually lead to their antitumor effects. 
Elucidation of the mechanisms of action of membrane-targeted APLs has served to 
identify new ways to regulate cancer cell death as well as to provide novel targets and 
approaches for cancer therapy. In this regard, lipid raft membrane domains, 
endoplasmic reticulum and mitochondria have turned out as major subcellular 
structures in the mechanism of action of APLs (Gajate and Mollinedo, this issue) as 
well as in the modulation of cell death. Membrane-related signaling and metabolic 
processes are critical events in APL action and in the regulation of cell demise. The 
studies shown here indicate that a remarkable and singular action of APLs lies in their 
effects on phospholipid and cholesterol metabolism (Marco et al., this issue) as well as 
on cholesterol-rich lipid raft membrane domains, as evidenced both in cancer cells 
(Gajate and Mollinedo, this issue) and model membranes (DynarowiczLątka and Hąc-
Wydro, this issue), thus leading to alterations in the membrane structure and 
composition that eventually affect signaling processes and the cell fate. Ongoing 
studies on the singular action of these fascinating compounds are unveiling new ways 
to regulate cell death as well as to identify new targets for cancer therapy. The studies 
on edelfosine and lipid rafts led for the first time to the involvement of lipid rafts in the 
regulation of apoptosis signaling, and highlighted the role of lipid rafts in cancer 
chemotherapy, thus supporting the potential of lipid rafts as novel and attractive targets 
in cancer therapy. This membrane-targeted action of APLs not only affects cell death 
signaling, but it also alters survival, adhesion and migration signaling (Chometon et al., 
this issue). The notion of the raft-targeted action of APLs established in the last thirteen 
years, favoring cell death signaling and inhibiting survival pathways, further supports 
the potential use of APLs in combination therapy. On these grounds, because of the 
rather unique mechanism of action of APLs, these compounds are appealing 
candidates to combine with other therapies, including radiotherapy (Verheij et al., this 
issue). New fluorescent APL analogs have been valuable tools to analyze the 
subcellular localization of APLs and have highlighted the role of endoplasmic reticulum 
and mitochondria in the action of APLs, but also have shown that the cytotoxicity 
exerted by these antitumor drugs largely depends on specific constituents of the cancer 
cells rather than only in the subcellular drug localization (Samadder et al., this issue). 
Studies in yeast also suggest that the cytotoxic effect of edelfosine does not only 
depend on the accumulation of edelfosine in certain subcellular structures. 
Interestingly, the effects of APLs on cancer cell invasion might also account, at least in 
part, for their antitumor action (Van slambrouck and Steelant, this issue).  
Thus, the interest for APLs lies not only for their potential role as antitumor drugs, but 
for their use as tools to study general biological processes, such as apoptosis/survival 
regulation and tumor cell invasion. This thematic issue gives an up-to-date overview on 
most relevant aspects regarding APLs as anticancer drugs, and provides some novel 
insights into the potential chemotherapeutic role of these molecules as anticancer 
drugs as well as into the corresponding underlying processes. 
 
 
 
 
 
